Literature DB >> 8202717

Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.

M Markman1.   

Abstract

The intraperitoneal delivery of cisplatin or carboplatin in the management of ovarian cancer is based on a sound pharmacokinetic rationale. Objective responses, including surgically documented complete responses, have been observed in patients with ovarian cancer who have previously responded to systemic platinum-based therapy. A precise role for intraperitoneal cisplatin or carboplatin in the management of ovarian cancer remains to be defined.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8202717

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  2 in total

1.  Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.

Authors:  C F Verschraegen; S Kumagai; R Davidson; B Feig; P Mansfield; S J Lee; D S Maclean; W Hu; A R Khokhar; Z H Siddik
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-29       Impact factor: 4.553

2.  Improvement of intraperitoneal chemotherapy for rat ovarian cancer using cisplatin-containing microspheres.

Authors:  S Kumagai; T Sugiyama; T Nishida; K Ushijima; M Yakushiji
Journal:  Jpn J Cancer Res       Date:  1996-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.